



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab)	Lot.No.:	P214064
Target:	PDCD1 / PD-1 / CD279	Catalog:	CHA078
Target Accession:	Q15116	Concentration :	1 mg/mL
Clonality:	Monoclonal	Isotype:	IgG4SP
Reactivity:	Human / Cynomolgus / Rhesus	Molecular Weight (kDa) :	150 kDa
Application:	FCM, Block, In Vivo, ELISA	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti- Human PD-1 (Pembrolizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of anti- human PD-1 (Pembrolizumab) is more than 95%, determined by SEC-HPLC.

Bioactivity: ELISA



Immobilized human PD-1 (His Tag, 2µg/mL) can bind to Anti- Human PD-1 (Pembrolizumab) with an EC50 of 0.0039 ug/mL.

Research in vivo



Anti- Human PD-1 (Pembrolizumab) inhibited the tumor growth of MC38 on human PD-1 mice. The result showed significant anti-tumor effects, with a tumor inhibition rate (TGI) of 44.0% at 0.18 mpk at D37.

The products are for research use only. Not for use in diagnostic procedures.